北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies
作者: Zhang, Y-y; Liu, D-h; Liu, K-y; Xu, L-p; Chen, H.; Han, W.; Wang, Y.; Huang, X-j
关键词: haploidentical ; hematopoietic SCT ; hematological malignancy
刊名: BONE MARROW TRANSPLANTATION
发表日期: 2014-04-01
DOI: 10.1038/bmt.2013.223
卷: 49, 期:4, 页:496-501
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]: BONE-MARROW-TRANSPLANTATION ; ACUTE-LEUKEMIA ; MISMATCHED/HAPLOIDENTICAL BLOOD ; CLINICAL-OUTCOMES ; HIGH-RISK ; RELAPSE ; GRAFT ; ALLOREACTIVITY ; HAPLOTYPE ; LYMPHOMA
英文摘要:

HLA-haploidentical hematopoietic SCT (HSCT) provides an opportunity for almost all patients who lack HLA-matched sibling donors. The donor availability can be increased by including the collateral related donors (CRDs). We compared clinical outcomes of patients with hematological malignancies, who underwent haploidentical HSCT from CRD (n=30) and immediate related donors (IRDs; n=120). In CRDs, 29 (96.7%) patients achieved sustained engraftment. In CRDs and IRDs, the median times of myeloid recovery were 13 (range 10-20 days) and 14 days (range 12-23 days), and the median times of platelet recovery were 18 (range 7-270) and 15 days (range 7-132 days; P=0.027). The incidences of II-IV acute GVHD were 27.6% versus 39.4% (P=0.058). The 2-year cumulative incidences of chronic GVHD (cGVHD) were 63.3% versus 57.8% (P=0.365). The 2-year incidence of extensive cGVHD of CRDs was significantly higher than that of IRDs (36.7% versus 20.2%, P=0.03). The 2-year incidences of relapse, 3-year probability of OS and leukemia-free survival for the two groups were 26.7% versus 14.8% (P=0.17), 56.7% versus 70.4% (P=0.224) and 50.0% versus 65.4% (P=0.103), respectively. This study shows that haploidentical HSCT from CRDs can provide a safe and effective treatment for patients with hematological malignancies. CRDs could be an alternative when there was no suitable IRDs.

语种: 英语
所属项目编号: 30971292 ; 7122193
项目资助者: National Clinical Key Specialties of China ; National Natural Science Foundation of China ; Beijing Natural Science Foundation
WOS记录号: WOS:000334500900005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/57324
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab, Beijing 100044, Peoples R China

Recommended Citation:
Zhang, Y-y,Liu, D-h,Liu, K-y,et al. HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies[J]. BONE MARROW TRANSPLANTATION,2014,49(4):496-501.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang, Y-y]'s Articles
[Liu, D-h]'s Articles
[Liu, K-y]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang, Y-y]‘s Articles
[Liu, D-h]‘s Articles
[Liu, K-y]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace